Content about Pneumococcal conjugate vaccine

January 7, 2014

Giving young children the influenza and pneumococcal vaccines together appears to increase their risk of fever, according to a study led by researchers from Columbia University Medical Center and the Centers for Disease Control and Prevention.

NEW YORK — Giving young children the influenza and pneumococcal vaccines together appears to increase their risk of fever, according to a study led by researchers from Columbia University Medical Center and the Centers for Disease Control and Prevention released Monday afternoon. However, the fever was brief, and medical care was sought for few children, supporting the routine immunization schedule for these vaccines, including the recommendation to administer them simultaneously. 

May 22, 2013

A new vaccine against pneumococcal disease appears as safe as an older one, according to a new study.

PASADENA, Calif. — A new vaccine against pneumococcal disease appears as safe as an older one, according to a new study.

The study, conducted by Kaiser Permanente and published Wednesday in the journal Vaccine, compared the new 13-valent vaccine with the seven-valent one used before 2010. The Food and Drug Administration approved the newer vaccine, called PCV13, in 2010 after a series of trials. The valent number refers to the number of varieties of pneumococcal disease the vaccine prevents.

February 26, 2013

A Virginia-based pharmacy school will collaborate with an alliance of more than 22,000 pharmacies around the country to find ways to promote and increase pneumococcal vaccinations among elderly and high-risk people.

LEESBURG, Va. — A Virginia-based pharmacy school will collaborate with an alliance of more than 22,000 pharmacies around the country to find ways to promote and increase pneumococcal vaccinations among elderly and high-risk people.

January 28, 2013

The Food and Drug Administration has approved a new use for a pneumococcal vaccine made by Pfizer, the drug maker said.

NEW YORK — The Food and Drug Administration has approved a new use for a pneumococcal vaccine made by Pfizer, the drug maker said.

Pfizer announced the approval of Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) for children and adolescents ages 6 years to 17 years for active immunization against the 13 Streptococcus pneumonia serotypes the vaccine covers. For this group, Prevnar 13 is administered as a one-time dose to patients who have never received it.

October 15, 2012

The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices has updated its recommendations for pneumococcal vaccine in high-risk adults.

ATLANTA — The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices has updated its recommendations for pneumococcal vaccine in high-risk adults.

ACIP now recommends the use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13) for high-risk adults ages 19 years or older. The committee recommends that PCV13 should be administered to eligible adults in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax 23), the vaccine currently recommended for these groups of adults.

January 3, 2012

The Food and Drug Administration has approved a Pfizer vaccine for Streptococcus pneumoniae in adults ages 50 years and older, the company said.

NEW YORK — The Food and Drug Administration has approved a Pfizer vaccine for Streptococcus pneumoniae in adults ages 50 years and older, the company said.

Pfizer announced the FDA approval of Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) as a single-dose for adults.

October 10, 2010

Humanity has come a long way since the days when people thought sickness came from...

March 17, 2010

A phase-3 clinical trial found that a pneumococcal disease vaccine was well-tolerated and immunogenic in...

February 23, 2010

The Food and Drug Administration has approved a vaccine for preventing pneumococcal disease in children,...